Bridgeway Capital Management LLC Cuts Holdings in Omeros Co. (NASDAQ:OMER)

Bridgeway Capital Management LLC reduced its position in shares of Omeros Co. (NASDAQ:OMER) by 3.8% during the 4th quarter, HoldingsChannel reports. The fund owned 155,100 shares of the biopharmaceutical company’s stock after selling 6,200 shares during the period. Bridgeway Capital Management LLC’s holdings in Omeros were worth $1,532,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the company. Truvestments Capital LLC raised its holdings in Omeros by 116.5% in the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 1,669 shares during the period. Tower Research Capital LLC TRC increased its position in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 1,972 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Omeros during the 4th quarter worth approximately $46,000. Picton Mahoney Asset Management lifted its position in shares of Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after buying an additional 4,404 shares in the last quarter. Finally, US Bancorp DE purchased a new position in shares of Omeros during the 4th quarter valued at approximately $81,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

OMER has been the subject of a number of research analyst reports. Needham & Company LLC restated a “hold” rating on shares of Omeros in a research report on Tuesday, April 1st. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a research report on Wednesday. Finally, StockNews.com cut Omeros from a “hold” rating to a “sell” rating in a report on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Omeros has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Down 2.1 %

Omeros stock opened at $6.18 on Friday. The company has a fifty day simple moving average of $7.43 and a 200-day simple moving average of $8.15. The firm has a market capitalization of $360.33 million, a price-to-earnings ratio of -2.68 and a beta of 2.42. Omeros Co. has a 52-week low of $3.00 and a 52-week high of $13.60.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.08. During the same quarter last year, the company posted ($0.15) earnings per share. On average, research analysts anticipate that Omeros Co. will post -3.09 EPS for the current fiscal year.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.